believed however, that art searching with respect to such monoclonal antibodies will also reveal the art (if any) relating to humanized and chimeric antibodies. Thus, it is believed that all such antibodies can and should be examined in this application, and such examination can be accomplished using a single search. Claims 1 and 22 have been amended, as shown above, to reflect Applicants' election to prosecute claims drawn to the use of hVEGF antagonists which comprise anti-VEGF antibodies.

The office action also set forth a Notice to Comply with Requirements for Patent Applications Containing Nucleotide Sequence and/or Amino Acid Sequence Disclosures. In accordance with the requirements of 37 CFR Sections 1.821-1.825, Applicants are providing herewith the paper copy of the Sequence Listing, along with a computer readable form of the Sequence Listing. The sequence disclosures in the Sequence Listing are fully supported by the specification as filed, and as such, do not introduce new matter. The various sequences were provided in Figures 14 and 15, as originally filed, and the Brief Description of the Drawings in the specification has now been amended to recite the SEQ ID NO:s which appear in the Sequence Listing. Entry of the Sequence Listing into the present specification is respectfully requested.

Respectfully yours,
GENENTECH, INC.

March 7 2000

Diane L. Marschang
Reg. No. 35,600

1 DNA Way
So. San Francisco, CA 94080-4990
Phone: (650) 225-5416
Fax: (650) 952-9881